To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Longitudinal tau and meta… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease

Journal article
Authors A. Leuzy
Claudia Cicognola
K. Chiotis
L. Saint-Aubert
L. Lemoine
N. Andreasen
Henrik Zetterberg
K. Q. Ye
Kaj Blennow
Kina Höglund
A. Nordberg
Published in European Journal of Nuclear Medicine and Molecular Imaging
Volume 46
Issue 5
Pages 1152-1163
ISSN 1619-7070
Publication year 2019
Published at Institute of Neuroscience and Physiology
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 1152-1163
Language en
Keywords Alzheimer's disease, Tau, CSF, PET imaging, [F-18]FDG, [F-18]THK5317, positron-emission-tomography, fluid amyloid-beta, cerebrospinal-fluid, glucose-metabolism, neurofibrillary pathology, phospho-tau, human brain, biomarkers, association, deposition, Radiology, Nuclear Medicine & Medical Imaging
Subject categories Radiology


Purpose Studies comparing CSF and PET tau biomarkers have included only commercial CSF assays examining specific phosphorylation sites (e.g. threonine 181, P-tau(181p)) and mid-domain tau (i.e. total tau, T-tau). Moreover, these studies did not examine CSF tau levels in relation to cerebral glucose metabolism. We thus aimed to examine CSF tau measures, using both commercial and novel assays, in relation to [F-18]THK5317 (tau) and [F-18]FDG PET (glucose metabolism). Methods Fourteen Alzheimer's disease (AD) patients (seven prodromal, seven dementia) underwent [F-18]THK5317 and [F-18]FDG PET studies, with follow-up performed in ten subjects (six prodromal, four dementia) after 17 months. In addition to commercial assays, novel measures capturing N-terminus+mid-domain (tau N-Mid) and C-terminally truncated (tau-368) fragments were included. Results While the levels of all forms of CSF tau were found to be inversely associated with baseline [F-18]FDG uptake, associations with baseline [F-18]THK5317 uptake varied in relation to the degree of isocortical hypometabolism ([F-18]FDG SUVR). Changes in the levels of the novel CSF markers tracked longitudinal changes in tracer uptake better than changes in P-tau(181p) and T-tau levels, and improved concordance with dichotomized regional [F-18]THK5317 measures. Conclusion Our findings suggest that neurodegeneration may modulate the relationship between CSF and PET tau biomarkers, and that, by comparison to P-tau(181p) and T-tau, tau-368 and tau N-Mid may better capturetau pathology and synaptic impairment.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?